Physician profile
Courtney Potts
NPI 1760181390
$6,351.80
in general payments reported to CMS, 2019-2025
20 companies · $2,110 in 2025
The $2,110 reported for 2025 was more than what 97% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,331 · 2024: $2,911 · 2025: $2,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,351.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $2,372.65 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $698.39 | 2023-2025 | Impella |
| Stryker Corporation | $673.64 | 2025 | Flowtriever, Artix Mt, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $474.87 | 2024-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $343.21 | 2024-2025 | Lifevest |
| Scpharmaceuticals INC. | $225.21 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $217.44 | 2023-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $214.80 | 2023-2025 | Verquvo |
| Amgen INC. | $199.07 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.61 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $182.91 | 2023-2025 | |
| Novo Nordisk INC | $147.25 | 2023-2025 | Wegovy |
| Recor Medical INC | $135.55 | 2025 | Paradise Ultrasound Renal Denervation System |
| Astrazeneca Pharmaceuticals Lp | $77.38 | 2023-2025 | Farxiga, Wainua |
| Abbott Laboratories | $65.43 | 2024 | Assurity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $54.23 | 2025 | |
| Pfizer INC. | $30.72 | 2023 | |
| Kiniksa Pharmaceuticals, Ltd. | $18.74 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $15.79 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $13.91 | 2025 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Potts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.